Materiały źródłowe

• #1 Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3378283/

  Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. […] Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. […] The current status of NAFLD therapy and an approach to its management is reviewed. […] The primary objective of any NAFLD therapy is improvement in steatohepatitis and fibrosis, with the ultimate goal of preventing CVD- and liver-related death. […] Nonpharmacological measures are aimed at reducing caloric intake and increasing physical activity levels. Weight loss and increased physical activity are effective in NAFLD treatment, and their role in CVD risk reduction is well established. […] Modest weight loss (7% to 10%) and exercise improve liver histology, insulin resistance (IR) and quality of life, and should form the backbone of any treatment strategy.

• #2 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Non-alcoholic fatty liver disease is the most prevalent hepatopathy, estimated at 30% in the general population. Current treatment for non-alcoholic fatty liver disease is based on dietary and exercise interventions that have been shown to be efficacious, even for reverting fibrosis. Unfortunately, compliance with general measures involving lifestyle modifications is very poor, making pharmacologic strategies a necessary option. At present, there are no treatments for non-alcoholic fatty liver disease approved by regulatory agencies, and the only ones with sufficient evidence and recommended by international societies are treatments with pioglitazone and vitamin E, which are not exempt from adverse effects. […] Hygienic-dietary measures are very important because they modify disease progression and are usually the basis of treatment of the comorbidities that tend to accompany NAFLD, such as the different components of metabolic syndrome.

• #3 Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

  https://www.eurekaselect.com/90067/article/current-treatment-strategies-non-alcoholic-fatty-liver-disease-nafld

  Nonalcoholic fatty liver disease (NAFLD) is recognized as the most common cause of chronic liver disease worldwide. […] Several therapeutic modalities that target these mechanisms are under investigation, but no proven treatment has yet emerged. […] Insulin sensitizers such as thiazolidinediones and metformin show promise, and several studies have explored the role of lipid lowering agents, antioxidants, and cytoprotective agents. […] Novel agents such as antiobesity drugs, selective cannabinoid-1 receptor blockers, and dual PPAR alpha and gamma agonists are also under investigation. […] NAFLD treatment currently focuses on reducing metabolic risk factors, with the mainstay of therapy focusing on life-style modifications such as gradual weight loss through diet and regular exercise.

• #4 Treatment for NAFLD & NASH – NIDDK

  https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/treatment

  Doctors recommend weight loss to treat nonalcoholic fatty liver disease, or NAFLD (also referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD). Weight loss can reduce fat in the liver. Weight loss can also reduce inflammation and fibrosis or scarring in the liver due to nonalcoholic steatohepatitis, or NASH (also referred to as metabolic dysfunction-associated steatohepatitis, or MASH). […] If you are overweight or have obesity, losing weight by making healthy food choices, limiting portion sizes, and being physically active can improve NAFLD either NAFL or NASH. Losing at least 3% to 5% of your body weight can reduce fat in the liver. You may need to lose up to 7% to 10% of your body weight to reduce liver inflammation and fibrosis. Physical activity alone, even without weight loss, is also beneficial.

• #5 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. The following lifestyle changes are important in managing your disease. […] This is one of the best treatments for NAFLD and NASH, because it moderates the conditions that contribute to fatty liver disease. Losing just 3 to 5 percent of your body weight can reduce fat in your liver; losing 7 percent can decrease inflammation as well. If you are overweight or obese, doctors typically recommend you gradually lose 7 to 10 percent of your body weight over the course of one year. Rapid weight loss through fasting is not recommended, as it can make NAFLD worse. […] While following a healthy diet and maintaining a normal body weight may not seem like a specific treatment, its essential to managing NAFLD and NASH.

• #6 MASLD, NAFLD and fatty liver disease – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/masld-nafld-and-fatty-liver-disease/

  Metabolic dysfunction-associated steatotic liver disease (MASLD) is a long-lasting liver condition caused by having too much fat in the liver. […] The main treatment is eating a well-balanced diet, being physically active and (if needed) losing weight. Research shows these can reduce liver fat and in some cases reverse MASLD. […] Treating MASLD with a healthy diet, physical activity and weight loss can slow or even reverse liver damage, especially if it is at an earlier stage. […] The main treatment is eating a healthy diet, being more physically active and (if needed) losing weight. This might seem like very general advice, but these steps all reduce liver fat and inflammation. For example, for people who are overweight, evidence shows losing 5 to 10% of their bodyweight can stop and sometimes even reverse liver damage.

• #7 MASLD, NAFLD and fatty liver disease – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/masld-nafld-and-fatty-liver-disease/

  There are currently no medicines available in the UK to specifically treat MASLD. But there is a lot of research being done to develop some. […] Whatever your weight, eating healthily and being more physically active can each help reduce liver fat and improve fatty liver disease. […] If you are overweight, the most important thing you can do to improve your condition is to lose weight. Research shows that losing 5 to 10% of your body weight can control and in some cases reverse MASLD. […] The aim is to generally eat and drink healthily most of the time and not have too much or too little of anything. […] Aim to do at least 2 hours of physical activity every week that gets you a bit out of breath.

• #8 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #9 Nonalcoholic fatty liver disease – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/diagnosis-treatment/drc-20354573

  Treatment for NAFLD usually starts with weight loss. This can be done by eating a healthy diet, limiting portion sizes and exercise. Losing weight may improve other health problems that lead to NAFLD. Typically, losing 10% of your body weight or more is recommended. But losing even 3% to 5% of your starting weight can have benefits. Weight-loss surgery or medicines also may be helpful for certain people. […] A new medicine is available to treat people who have NASH with moderate to severe liver scarring. Resmetirom (Rezdiffra) can help reduce the amount of fat that collects in the liver. This medicine is not recommended for people with cirrhosis. For those who have cirrhosis due to NASH, a liver transplant may be needed.

• #10 Natural Remedies for Fatty Liver Disease

  https://www.healthline.com/health/home-remedies-for-fatty-liver

  Nonalcoholic fatty liver disease (NAFLD) is caused by a buildup of fat in the liver. Along with medications, diet and lifestyle changes are among the most effective management strategies. […] The American Association for the Study of Liver Diseases (AASLD)’s 2017 guide identifies weight loss as a critical part of improving NAFLD progression and symptoms. […] The guide recommends that people living with obesity and NAFLD lose between 3-5% of their body weight to reduce fat buildup in the liver. […] It also states that losing between 7-10% of body weight can improve other symptoms of NAFLD, such as inflammation, fibrosis, and scarring. […] Research from 2017 suggests that the Mediterranean diet may help to reduce liver fat, even without weight loss. […] According to research, coffee offers a number of protective benefits for the liver.

• #11 Treatment for NAFLD & NASH – NIDDK

  https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/treatment

  Doctors recommend weight loss to treat nonalcoholic fatty liver disease, or NAFLD (also referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD). Weight loss can reduce fat in the liver. Weight loss can also reduce inflammation and fibrosis or scarring in the liver due to nonalcoholic steatohepatitis, or NASH (also referred to as metabolic dysfunction-associated steatohepatitis, or MASH). […] If you are overweight or have obesity, losing weight by making healthy food choices, limiting portion sizes, and being physically active can improve NAFLD either NAFL or NASH. Losing at least 3% to 5% of your body weight can reduce fat in the liver. You may need to lose up to 7% to 10% of your body weight to reduce liver inflammation and fibrosis. Physical activity alone, even without weight loss, is also beneficial.

• #12 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  A healthy diet, weight loss, and exercise are first-line therapeutic measures to reduce insulin resistance in patients with nonalcoholic fatty liver disease. […] Although there is no established treatment, a healthy low-fat diet may have benefits independent of weight loss. […] A meta-analysis of 49 randomized controlled trials found that weight loss was safe in patients with nonalcoholic fatty liver disease, and it improved liver histology. […] Three Cochrane reviews found insufficient evidence to support the use of bile acids (e.g., ursodeoxycholic acid), antioxidant supplements, metformin (Glucophage), or thiazolidinediones in the absence of diabetes in patients with nonalcoholic fatty liver disease. […] Another meta-analysis of 49 randomized controlled trials found that thiazolidinediones (especially pioglitazone [Actos]) improved steatosis and inflammation but were associated with a weight increase of 4.5 to 11 lb (2 to 5 kg) in 66% to 75% of patients and edema in 4% to 10% of patients.

• #13 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. The following lifestyle changes are important in managing your disease. […] This is one of the best treatments for NAFLD and NASH, because it moderates the conditions that contribute to fatty liver disease. Losing just 3 to 5 percent of your body weight can reduce fat in your liver; losing 7 percent can decrease inflammation as well. If you are overweight or obese, doctors typically recommend you gradually lose 7 to 10 percent of your body weight over the course of one year. Rapid weight loss through fasting is not recommended, as it can make NAFLD worse. […] While following a healthy diet and maintaining a normal body weight may not seem like a specific treatment, its essential to managing NAFLD and NASH.

• #14 Non-Alcoholic Fatty Liver Disease | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/digestive-and-liver-health/fatty-liver-disease-non-alcoholic

  Active research is ongoing, but for now there are no FDA approved medications specifically for the treatment of NAFLD/NASH. […] Improving liver fat and inflammation is possible when people lose weight and/or modify their lifestyle. This is the first line treatment for NAFLD/NASH. […] Lifestyle modification includes adopting a healthy diet as well as increasing physical activity. […] Losing 10% of your total current body weight increases the likelihood that the amount of liver fat and inflammation will improve. Weight loss should be gradual (a goal of 1-3 pounds per week), as rapid weight loss can actually worsen liver disease. […] Patients with NASH diagnosed with a liver biopsy and who do not have diabetes, significant heart disease or cirrhosis will sometimes be asked to start Vitamin E as this is thought to help reduce liver inflammation.

• #15 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #16 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  To date, there is no specific drug treatment for NAFLD, however it is believed that a combination of treatment goals (lifestyle adjustments, increasing physical activity and smoking/ alcohol cessation) can be beneficial. […] NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD.

• #17 Metabolic dysfunction–associated steatotic liver disease – Wikipedia

  https://en.wikipedia.org/wiki/Metabolic_dysfunction%E2%80%93associated_steatotic_liver_disease

  A combination of improved diet and exercise, rather than either alone, appears to best help manage NAFLD and reduce insulin resistance. […] The EASL recommends energy restriction of 500-1000 kcal per week less than the normal daily diet, a target of 7-10% weight loss for obese/overweight MASLD, a low- to moderate-fat, and moderate- to high-carbohydrate diet, or a low-carbohydrate ketogenic or high-protein diet such as the Mediterranean diet, and avoiding all beverages and food containing fructose. […] The role of coffee consumption for NAFLD treatment is unclear though some studies indicate that regular coffee consumption may have protective effects. […] Vitamin E does not improve established liver fibrosis in those with MASLD but seems to improve certain markers of liver function and reduces inflammation and fattiness of the liver in some people with MASLD. […] Resmetirom (Rezdiffra) was approved for medical use in the United States in March 2024 for the treatment of noncirrhotic nonalcoholic steatohepatitis.

• #18 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  Adopting a healthy lifestyle is the main way of managing NAFLD. […] For example, it can help to: lose weight you should aim for a BMI of 18.5 to 24.9 (use the BMI calculator to work out your BMI); losing more than 10% of your weight can remove some fat from the liver and improve NASH if you have it […] eat a healthy diet try to have a balanced diet high in fruits, vegetables, protein and carbohydrates, but low in fat, sugar and salt; eating smaller portions of food can help, too […] exercise regularly aim to do at least 150 minutes of moderate-intensity activity, such as walking or cycling, a week; all types of exercise can help improve NAFLD, even if you do not lose weight […] NAFLD is not caused by alcohol, but drinking may make it worse. It’s therefore advisable to cut down or stop drinking alcohol.

• #19 Natural Remedies for Fatty Liver Disease

  https://www.healthline.com/health/home-remedies-for-fatty-liver

  The same research reported that among people with NAFLD, regular coffee consumption reduces overall liver damage. […] According to research from 2017, NAFLD is often associated with a sedentary lifestyle. […] Dietary sugars such as fructose and sucrose have been linked to the development of NAFLD. […] According to research, NAFLD can make it harder for your body to manage cholesterol on its own. […] Research suggests that taking an omega-3 supplement may reduce liver fat and improve cholesterol levels. […] According to research from 2019, even moderate consumption of alcohol can lead to disease progression in individuals with NAFLD. […] Vitamin E is one antioxidant that may reduce inflammation caused by NAFLD. […] According to a 2018 review of studies, while some research is promising, more studies are needed to understand who can benefit from this supplement and how. […] There are currently no approved medical treatments for NAFLD, though there are some in development. […] One such treatment is pioglitazone, a medication typically prescribed for type 2 diabetes. […] Lifestyle and dietary changes are currently the most effective options for managing NAFLD.

• #20 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  To date, there is no specific drug treatment for NAFLD, however it is believed that a combination of treatment goals (lifestyle adjustments, increasing physical activity and smoking/ alcohol cessation) can be beneficial. […] NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD.

• #21 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  To date, there is no specific drug treatment for NAFLD, however it is believed that a combination of treatment goals (lifestyle adjustments, increasing physical activity and smoking/ alcohol cessation) can be beneficial. […] NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD.

• #22 Fatty liver disease: What it is and what to do about it – Harvard Health

  https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746

  Here’s what we know helps: […] Weight loss of roughly 5% of your body weight might be enough to improve abnormal liver tests and decrease the fat in the liver. […] Losing between 7% and 10% of body weight seems to decrease the amount of inflammation and injury to liver cells, and it may even reverse some of the damage of fibrosis. […] It appears that aerobic exercise also leads to decreased fat in the liver, and with vigorous intensity, possibly also decreased inflammation independent of weight loss. […] Some studies suggest that the Mediterranean diet may also decrease the fat in the liver. […] Some studies showed that patients with NAFLD who drank coffee (about two cups every day) had a decreased risk in fibrosis.

• #23 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  To date, there is no specific drug treatment for NAFLD, however it is believed that a combination of treatment goals (lifestyle adjustments, increasing physical activity and smoking/ alcohol cessation) can be beneficial. […] NAFLD patients, whether living with obesity are not, should be encouraged and educated to partake in a healthy lifestyle approach, which exists irrespective of weight-loss. […] A healthy diet i.e. reduction of caloric intake and high-glycaemic index (GI) foods, increased consumption of monounsaturated fatty acids, omega-3 fatty acids, fibers, and specific protein sources such as fish and poultry are suggested to have beneficial effects. […] Studies suggest that a Mediterranean diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monosaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD.

• #24 Treatment for NAFLD & NASH – NIDDK

  https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/treatment

  Doctors recommend weight loss to treat nonalcoholic fatty liver disease, or NAFLD (also referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD). Weight loss can reduce fat in the liver. Weight loss can also reduce inflammation and fibrosis or scarring in the liver due to nonalcoholic steatohepatitis, or NASH (also referred to as metabolic dysfunction-associated steatohepatitis, or MASH). […] If you are overweight or have obesity, losing weight by making healthy food choices, limiting portion sizes, and being physically active can improve NAFLD either NAFL or NASH. Losing at least 3% to 5% of your body weight can reduce fat in the liver. You may need to lose up to 7% to 10% of your body weight to reduce liver inflammation and fibrosis. Physical activity alone, even without weight loss, is also beneficial.

• #25 Fatty liver disease: What it is and what to do about it – Harvard Health

  https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746

  Here’s what we know helps: […] Weight loss of roughly 5% of your body weight might be enough to improve abnormal liver tests and decrease the fat in the liver. […] Losing between 7% and 10% of body weight seems to decrease the amount of inflammation and injury to liver cells, and it may even reverse some of the damage of fibrosis. […] It appears that aerobic exercise also leads to decreased fat in the liver, and with vigorous intensity, possibly also decreased inflammation independent of weight loss. […] Some studies suggest that the Mediterranean diet may also decrease the fat in the liver. […] Some studies showed that patients with NAFLD who drank coffee (about two cups every day) had a decreased risk in fibrosis.

• #26 MASLD, NAFLD and fatty liver disease – British Liver Trust

  https://britishlivertrust.org.uk/information-and-support/liver-conditions/masld-nafld-and-fatty-liver-disease/

  There are currently no medicines available in the UK to specifically treat MASLD. But there is a lot of research being done to develop some. […] Whatever your weight, eating healthily and being more physically active can each help reduce liver fat and improve fatty liver disease. […] If you are overweight, the most important thing you can do to improve your condition is to lose weight. Research shows that losing 5 to 10% of your body weight can control and in some cases reverse MASLD. […] The aim is to generally eat and drink healthily most of the time and not have too much or too little of anything. […] Aim to do at least 2 hours of physical activity every week that gets you a bit out of breath.

• #27 Non-alcoholic Fatty Liver Disease: Causes and Diagnoses

  https://patient.info/healthy-living/alcohol-and-liver-disease/non-alcoholic-fatty-liver-disease

  Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells. […] If you are obese or overweight, the main treatment advised for NAFLD is usually gradual weight loss and regular exercise. This not only helps with NAFLD, but will help reduce your risk of developing cardiovascular problems. […] Most cases of NAFLD are linked to being obese or overweight. There is good evidence that a programme of gradual weight loss and regular exercise can reduce the amount of fat in your liver. So, if you have simple fatty liver or mild NASH, this may prevent or delay the progression of NAFLD. It may reduce your chance of developing cirrhosis – a condition where normal liver tissue is replaced by a lot of scar tissue (fibrosis). […] Aerobic exercise and diet changes are the most effective way to manage NAFLD. Try to aim for 150-200 minutes of moderate-intensity exercise a week – split over 3-5 sessions.

• #28 Fatty liver disease: What it is and what to do about it – Harvard Health

  https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746

  Here’s what we know helps: […] Weight loss of roughly 5% of your body weight might be enough to improve abnormal liver tests and decrease the fat in the liver. […] Losing between 7% and 10% of body weight seems to decrease the amount of inflammation and injury to liver cells, and it may even reverse some of the damage of fibrosis. […] It appears that aerobic exercise also leads to decreased fat in the liver, and with vigorous intensity, possibly also decreased inflammation independent of weight loss. […] Some studies suggest that the Mediterranean diet may also decrease the fat in the liver. […] Some studies showed that patients with NAFLD who drank coffee (about two cups every day) had a decreased risk in fibrosis.

• #29 How to Reverse Nonalcoholic Fatty Liver Disease

  https://www.healthline.com/health/how-to-clean-a-fatty-liver

  Experts recommend the Mediterranean diet to help reverse the effects of nonalcoholic fatty liver disease. […] Engaging in both aerobic exercise and resistance training can help to reduce nonalcoholic fatty liver disease. […] In a 2013 study of 154 people with nonalcoholic fatty liver disease (NAFLD), exercise and diet interventions resulted in the remission of fatty liver disease in 64% of participants. […] Based on current research, lifestyle changes are more helpful than medications. […] If you have NAFLD, it will depend on how quickly you lose weight. But remember, be careful not to lose weight too quickly. […] Taking steps to reduce the fat in your liver can help to improve your overall health and ideally work to prevent the progression to more severe liver disease. […] Reversing fatty liver disease requires diet and lifestyle measures to help you lose fat and lower inflammation. Living a healthier lifestyle wont only help reduce fat in your liver. It will also improve your overall health and can lower the incidence of other obesity-related conditions such as diabetes.

• #30 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #31 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  For patients with biopsy-proven NASH, where lifestyle intervention has failed, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered. […] Pioglitazone appears to be an effective treatment for NASH, but there are also some concerns about its long-term safety. […] Vitamin E is an antioxidant that has recently been shown to have beneficial effects on histology in non-diabetic patients with NASH. […] Lifestyle interventions aimed at weight loss and increased activity are essential for all patients with NAFLD and if sustained are effective in the treatment of NAFLD. For patients who fail lifestyle intervention, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered for those with advanced, but pre-cirrhotic, NASH.

• #32 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] The FDA approved Rezdiffra under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and address an unmet medical need, based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.

• #33 FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease > News > Yale Medicine

  https://www.yalemedicine.org/news/rezdiffra-for-nash-nonalcoholic-steatohepatitis

  Rates of a serious form of liver disease have grown, but there have been no medications to treat it until now. In March, the U.S. Food and Drug Administration (FDA) approved a pill called resmetirom, sold under the brand name Rezdiffra, for NASH (nonalcoholic steatohepatitis). […] Rezdiffra is approved for adults with NASH who have moderate to advanced scarring of the liver, which is the case for an estimated 6 to 8 million Americans. […] This new medication, however, has been shown to improve scarring in about 25% of people who take it. […] Rezdiffra, made by Madrigal Pharmaceuticals, is a daily pill that activates a thyroid hormone receptor that reduces liver fat accumulation. […] Results from an ongoing Phase III clinical trial were published in The New England Journal of Medicine. Resmetirom, which was tested at two dose strengths, was shown to resolve NASH without a worsening of fibrosis in 26% (at the lower dose) and 30% (at the higher dose) of patients compared to 10% in the placebo group. The trial also showed that the drug improved fibrosis by at least one stage in 24% (at the lower dose) and 26% (at the higher dose) of the patients, compared to 14% in the placebo group.

• #34 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] The FDA approved Rezdiffra under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and address an unmet medical need, based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.

• #35 FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA

  https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. […] Todays approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise. […] Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. […] At 12 months, liver biopsies showed that a greater proportion of subjects who were treated with Rezdiffra achieved NASH resolution or an improvement in liver scarring as compared with those who received the placebo. […] The FDA approved Rezdiffra under the accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and address an unmet medical need, based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.

• #36 Non-Alcoholic Fatty Liver Disease: Can You Reverse It?

  https://www.webmd.com/fatty-liver-disease/reverse-nonalcoholic-fatty-liver-disease

  Research suggests that losing excess weight is the single best thing you can do to control or reverse MASLD. A good goal is to lose 10% of your total body weight, but even a loss of 3% to 5% can improve your liver health. […] A fatty liver is linked to several other health conditions. Treat those issues and you can help reverse MASLD, too. […] Shifts in your diet may help you lose weight, but there are other payoffs as well. They can improve your general health and lower the amount of fat in your liver. […] Alcohol can cause fat to build up in your liver. It also can damage the organ. You should avoid alcohol if you have MASLD. […] No drugs are approved specifically to treat MASLD. One drug, resmetirom (Rezdiffra), is approved to treat the advanced stage of the condition, called metabolic dysfunction-associated liver disease (MASH) with greater degrees of fibrosis. […] Some studies have found that vitamin E seemed to improve how well some peoples livers worked, but the science is not settled. If youre interested in trying this supplement, talk to your doctor first.

• #37 FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease > News > Yale Medicine

  https://www.yalemedicine.org/news/rezdiffra-for-nash-nonalcoholic-steatohepatitis

  Rates of a serious form of liver disease have grown, but there have been no medications to treat it until now. In March, the U.S. Food and Drug Administration (FDA) approved a pill called resmetirom, sold under the brand name Rezdiffra, for NASH (nonalcoholic steatohepatitis). […] Rezdiffra is approved for adults with NASH who have moderate to advanced scarring of the liver, which is the case for an estimated 6 to 8 million Americans. […] This new medication, however, has been shown to improve scarring in about 25% of people who take it. […] Rezdiffra, made by Madrigal Pharmaceuticals, is a daily pill that activates a thyroid hormone receptor that reduces liver fat accumulation. […] Results from an ongoing Phase III clinical trial were published in The New England Journal of Medicine. Resmetirom, which was tested at two dose strengths, was shown to resolve NASH without a worsening of fibrosis in 26% (at the lower dose) and 30% (at the higher dose) of patients compared to 10% in the placebo group. The trial also showed that the drug improved fibrosis by at least one stage in 24% (at the lower dose) and 26% (at the higher dose) of the patients, compared to 14% in the placebo group.

• #38 Diagnosis and management of non-alcoholic fatty liver disease (NAFLD) – American Gastroenterological AssociationAGA Logo_Horizontal

  https://gastro.org/clinical-guidance/diagnosis-and-management-of-non-alcoholic-fatty-liver-disease-nafld/

  21. Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. […] 23. Ursodeoxycholic acid (UDCA) is not recommended for the treatment of NAFLD or NASH. […] 24. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH but they may be considered as the first line agents to treat hypertriglyceridemia in patients with NAFLD. […] 43. Intensive lifestyle modification improves aminotransferases and liver histology in children with NAFLD and thus should be the first line of treatment. […] 44. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed. The effect of metformin administered at a higher dose is not known. […] 45. Vitamin E 800 IU/day (RRR α–tocopherol) offers histological benefits to children with biopsy-proven NASH or borderline NASH but confirmatory studies are needed before it’s use can be recommended in clinical practice.

• #39 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #40 Diagnosis and management of non-alcoholic fatty liver disease (NAFLD) – American Gastroenterological AssociationAGA Logo_Horizontal

  https://gastro.org/clinical-guidance/diagnosis-and-management-of-non-alcoholic-fatty-liver-disease-nafld/

  21. Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. […] 23. Ursodeoxycholic acid (UDCA) is not recommended for the treatment of NAFLD or NASH. […] 24. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH but they may be considered as the first line agents to treat hypertriglyceridemia in patients with NAFLD. […] 43. Intensive lifestyle modification improves aminotransferases and liver histology in children with NAFLD and thus should be the first line of treatment. […] 44. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed. The effect of metformin administered at a higher dose is not known. […] 45. Vitamin E 800 IU/day (RRR α–tocopherol) offers histological benefits to children with biopsy-proven NASH or borderline NASH but confirmatory studies are needed before it’s use can be recommended in clinical practice.

• #41 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #42 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. […] Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. […] A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #43 Diagnosis and management of non-alcoholic fatty liver disease (NAFLD) – American Gastroenterological AssociationAGA Logo_Horizontal

  https://gastro.org/clinical-guidance/diagnosis-and-management-of-non-alcoholic-fatty-liver-disease-nafld/

  21. Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. […] 23. Ursodeoxycholic acid (UDCA) is not recommended for the treatment of NAFLD or NASH. […] 24. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH but they may be considered as the first line agents to treat hypertriglyceridemia in patients with NAFLD. […] 43. Intensive lifestyle modification improves aminotransferases and liver histology in children with NAFLD and thus should be the first line of treatment. […] 44. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed. The effect of metformin administered at a higher dose is not known. […] 45. Vitamin E 800 IU/day (RRR α–tocopherol) offers histological benefits to children with biopsy-proven NASH or borderline NASH but confirmatory studies are needed before it’s use can be recommended in clinical practice.

• #44 Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3378283/

  Insulin sensitizers, such as metformin and thiazolidinediones (TZDs), have been fairly well studied. […] Metformin has been evaluated in several small studies of nondiabetic NAFLD patients. […] The TZD class of drugs has held promise in the treatment of NAFLD due to its beneficial impact on IR, hepatocyte fatty acid metabolism and adiponectin levels. […] Overall, the results of trials of TZDs for NAFLD suggest some benefit from this class of drugs. […] Vitamin E treatment resulted in improvements in hepatocellular ballooning and NAS in both trials. […] Presently, the mainstay of treatment for NAFLD is the adoption of lifestyle changes aimed at increased physical activity and moderate, sustained weight loss. […] The controversy regarding vitamin E continues. It likely has a role in selected NAFLD patients; however, its widespread use will likely be tempered by the as yet uncertain relationship between vitamin E and all-cause mortality. […] Effective and safe treatments for this disease are desperately needed.

• #45 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  Patients with NAFLD should not consume heavy amounts of alcohol; data are insufficient to make recommendations with regard to nonheavy alcohol consumption. […] Pharmacologic treatments should be limited to individuals with biopsy-proven NASH and fibrosis. […] Vitamin E 800 IU/day improves liver histology in nondiabetic adults with biopsy-proven NASH; it should therefore be considered as a first-line pharmacotherapy for this patient population, and the risks and benefits should be discussed with the patient prior to starting treatment. […] Omega-3 fatty acids may be considered for hypertriglyceridemia in patients with NAFLD, but it is premature to recommend them for the specific treatment of NAFLD or NASH. The 2023 AASLD guidelines also recommend lifestyle changes and supplementation with omega-3 fatty acids, icosapent ethyl, or fibrates.

• #46 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  For patients with biopsy-proven NASH, where lifestyle intervention has failed, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered. […] Pioglitazone appears to be an effective treatment for NASH, but there are also some concerns about its long-term safety. […] Vitamin E is an antioxidant that has recently been shown to have beneficial effects on histology in non-diabetic patients with NASH. […] Lifestyle interventions aimed at weight loss and increased activity are essential for all patients with NAFLD and if sustained are effective in the treatment of NAFLD. For patients who fail lifestyle intervention, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered for those with advanced, but pre-cirrhotic, NASH.

• #47 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #48 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #49 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/24/3/2844

  There is no current specific drug for NAFLD therapy; however, it is widely believed that weight loss is the most critical intervention for obesity and NAFLD. […] In recent years, international guidelines have strongly recommended a target of 7–10% weight loss to be achieved through a healthy structured diet and physical activity. […] Multiple drugs for limiting NAFLD development and progression have been examined, although none is currently specifically licensed for NAFLD treatment. […] Pioglitazone, a thiazolidinedione derivative, is a potent activator of the nuclear receptor PPARγ (peroxisome proliferator-activated receptor γ), which is highly expressed in fat tissue, with an important role in adipocyte differentiation as well as in lipid and glucose metabolism. […] The efficacy of vitamin E can reduce oxidative stress, and vitamin E has thus been evaluated in NASH cases, which is supported by currently available guidelines as potential therapy in select NASH cases.

• #50 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  Metformin is not recommended as a specific treatment for liver disease in adults with NASH. […] Semaglutide can be considered for its approved indications (type 2 diabetes, obesity) in those with NASH (cardiovascular benefit, improves NASH). Similarly, pioglitazone improves NASH and can be considered in those with NASH and type 2 diabetes. […] Pioglitazone may be used to treat steatohepatitis in both patients with and without type 2 diabetes with biopsy-proven NASH, but the risks and benefits should be thoroughly discussed with the patient prior to initiation of treatment. […] Consider bariatric surgery as a treatment option in those who meet the criteria for metabolic weight loss surgery (resolves NAFLD or NASH in most patients without cirrhosis; lowers mortality from cardiovascular disease and malignancy).

• #51 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. […] Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. […] A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #52 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  A healthy diet, weight loss, and exercise are first-line therapeutic measures to reduce insulin resistance in patients with nonalcoholic fatty liver disease. […] Although there is no established treatment, a healthy low-fat diet may have benefits independent of weight loss. […] A meta-analysis of 49 randomized controlled trials found that weight loss was safe in patients with nonalcoholic fatty liver disease, and it improved liver histology. […] Three Cochrane reviews found insufficient evidence to support the use of bile acids (e.g., ursodeoxycholic acid), antioxidant supplements, metformin (Glucophage), or thiazolidinediones in the absence of diabetes in patients with nonalcoholic fatty liver disease. […] Another meta-analysis of 49 randomized controlled trials found that thiazolidinediones (especially pioglitazone [Actos]) improved steatosis and inflammation but were associated with a weight increase of 4.5 to 11 lb (2 to 5 kg) in 66% to 75% of patients and edema in 4% to 10% of patients.

• #53 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #54 The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/22/24/13219

  The new therapeutic approaches in the treatment of NAFLD are targeting some of the many pathophysiological mechanisms involved in the development of NAFLD […] The new therapeutic algorithm for NAFLD is shown in Figure 2. […] Lifestyle modification using diet and exercise to achieve weight loss remains a first-line intervention in patients with NAFLD. […] Vitamin E is well known as an antioxidant and is expected for the treatment of NASH. […] Obeticholic acid (OCA), a ligand of FXR, is a synthetic derivate of natural bile acid chenodeoxycholic acid. […] PPAR-γ agonist, pioglitazone, is the most used one. […] As previously mentioned, GLP-1 is a hormone which stimulates glucose-dependent insulin secretion and inhibits glucagon secretion, thus regulating plasma glucose levels. […] SGLT2 inhibitors are a class of antidiabetic agents which induce moderate weight loss and reduce body fat, mainly by increasing urinary glucose excretion.

• #55 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  https://my.clevelandclinic.org/health/diseases/22437-non-alcoholic-fatty-liver-disease

  Metabolic dysfunction-associated steatotic liver disease (MASLD) is when fat builds up in your liver. It once was called nonalcoholic fatty liver disease (NAFLD). […] Losing weight and becoming more active may slow down or reverse liver damage from MASLD. […] Early diagnosis and treatment can keep MASLD from getting worse. […] Treatment for MASLD usually starts with weight loss. Your healthcare provider will also treat conditions like diabetes, high cholesterol and high blood pressure, which cause MASLD. […] Losing weight makes a difference in your liver health. Reducing excess fat in your liver helps with inflammation that leads to cirrhosis. […] Your provider may recommend meal plans like the Mediterranean diet or the DASH diet. […] Your healthcare provider may recommend weight loss medications like GLP-1 agonists if you have diabetes and/or obesity.

• #56 Differences Between ALD and NAFLD | Pri-Med

  https://www.pri-med.com/blog/2022/ald-nafld-differences

  Treatment for alcohol-related liver disease includes abstinence from alcohol, nutritional therapy, and corticosteroids. […] The treatment of nonalcohol-related liver disease mainly involves weight loss with lifestyle modifications along with the addition of treatments for diabetes, like thiazolidinediones or glucagon-like peptide 1 agonists. […] Studies have shown that weight reduction by 3-5% reduces steatosis, and 5-7% weight loss resolves NASH. […] Recently, clinicians have praised the use of a glucagon-like peptide 1 agonist, liraglutide, since the medication treats type 2 diabetes and affords people weight loss. […] Recent evidence has shown that liraglutide can also be therapeutic for NAFLD. […] Experts also recommend treating with lipid-lowering agents since metabolic syndrome is characterized by hypercholesterolemia and hypertriglyceridemia.

• #57 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/24/3/2844

  GLP-1 agonists show prolonged half-lives compared with endogenous GLP-1 but exert similar effects, which stimulate insulin secretion, inhibit glucagon secretion and reduce liver glucose production. […] SGLT-2 suppressors, as the latest group of antidiabetic medications, inhibit kidney glucose reabsorption, which results in prominent glycosuria. […] Multiple drugs with diverse mechanisms of action, targeting lipid metabolism, inflammation or fibrosis have been developed for NASH therapy. […] Bariatric surgery ameliorates liver fat and may even alleviate all histological lesions in NASH, e.g., fibrosis. […] A combination of pharmacological treatment and bariatric surgery may be a better option.

• #58 FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease > News > Yale Medicine

  https://www.yalemedicine.org/news/rezdiffra-for-nash-nonalcoholic-steatohepatitis

  Anti-obesity medications, such as semaglutide (Wegovy) and tirzepatide (Zepound), can help treat fatty liver disease and potentially stop it from advancing to NASH, but once someone has NASH, these drugs have not yet been proven to reverse it, Dr. Mehal says. However, clinical trials are ongoing, and the early data is very encouraging that these medications will be effective for NASH, he adds. […] Rezdiffra is meant for adults with NASH who have well-developed, but not extremely severe scarring in their liver, and it should be used along with a healthy diet and an active lifestyle, says Dr. Mehal.

• #59 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Currently, there are many drugs in development for NAFLD. Therapeutic strategy in the near future must take into account numerous factors, such as grade/stage of the disease, comorbidities of each patient, and genetic factors. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner. […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels.

• #60 Treating inflammation to combat non-alcoholic fatty liver disease in: Journal of Endocrinology Volume 256 Issue 1 (2023)

  https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0194.xml

  As some of these approaches did not demonstrate convincing efficacy as monotherapies, a rational and personalized combination of therapeutic interventions may be needed for the near future. […] Currently, no specific pharmacotherapy has been approved for the treatment of NASH. Thus, current treatment strategies focus on optimizing the pharmacotherapy of comorbidities (e.g. for type 2 diabetes) and promoting weight loss, either by lifestyle changes and/or bariatric surgery. […] More recently, pharmacotherapies demonstrated effective weight loss by targeting glucagon-like peptide (GLP-1) such as semaglutide […] However, their long-term effects on NASH fibrosis and liver-related outcomes remain to be demonstrated. […] In general, pharmacological therapeutic approaches have been proposed that target the different steps of pathogenesis.

• #61 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/24/3/2844

  GLP-1 agonists show prolonged half-lives compared with endogenous GLP-1 but exert similar effects, which stimulate insulin secretion, inhibit glucagon secretion and reduce liver glucose production. […] SGLT-2 suppressors, as the latest group of antidiabetic medications, inhibit kidney glucose reabsorption, which results in prominent glycosuria. […] Multiple drugs with diverse mechanisms of action, targeting lipid metabolism, inflammation or fibrosis have been developed for NASH therapy. […] Bariatric surgery ameliorates liver fat and may even alleviate all histological lesions in NASH, e.g., fibrosis. […] A combination of pharmacological treatment and bariatric surgery may be a better option.

• #62 Metabolic dysfunction–associated steatotic liver disease – Wikipedia

  https://en.wikipedia.org/wiki/Metabolic_dysfunction%E2%80%93associated_steatotic_liver_disease

  Metabolic dysfunctionassociated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a type of chronic liver disease. This condition is diagnosed when there is excessive fat build-up in the liver (hepatic steatosis), and at least one metabolic risk factor. […] Treatment for MASLD is weight loss by dietary changes and exercise; bariatric surgery can improve or resolve severe cases. […] There is some evidence for SGLT-2 inhibitors, GLP-1 agonists, pioglitazone, and vitamin E in the treatment of MASLD. […] In March 2024, resmetirom was the first drug approved by the FDA for MASH. […] Weight loss is the most effective treatment for MASLD and MASH. A loss of 5% to 10% body weight is recommended and has shown regression of liver damage, with 10% to 40% weight loss completely reversing MASH without cirrhosis.

• #63 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  Therefore, pharmacologic treatment is and will continue to be at the core of management of those patients. […] At present, the treatments recommended by the American Association for the Study of Liver Diseases (AASLD) are vitamin E and pioglitazone in patients with NASH, but they are not exempt from adverse effects. […] Pioglitazone improves adipose tissue insulin sensitivity, promoting free fatty acid deposit in that tissue in a nonectopic manner (e.g., liver, pancreas). […] Vitamin E is an antioxidant, and the focus of its use is to improve the oxidative stress present in NASH. […] Pentoxifylline is a phosphodiesterase inhibitor with hemorrheologic and antioxidant properties through reducing tumor necrosis factor alpha levels. […] Treatment with GLP-1 agonists is approved for diabetes and obesity.

• #64 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis. […] Fibrates, statins, and omega-3 fatty acids produce modest improvement in AST levels but do not offer advantages over weight loss and increased physical activity. […] A systematic review of two randomized trials and four prospective cohort studies found that pentoxifylline reduced AST and ALT levels, although the study did not examine improvements in patient morbidity or mortality.

• #65 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  There is no definitive pharmacologic therapy approved for treatment of nonalcoholic fatty liver disease (NAFLD). However, in the appropriate clinical setting, consider medications approved to treat the associated comorbidities that have potential benefit in NAFLD. Thus, management of NAFLD should include treating the associated obesity, hyperlipidemia, insulin resistance, and type 2 diabetes. […] The American Association for the Study of Liver Diseases (AASLD) indicates that statins are safe and recommended to lower the risk of cardiovascular disease in those with conditions across the NAFLD spectrum, including compensated cirrhosis. However, for patients with decompensated cirrhosis, there are only limited data regarding the safety and efficacy of statins, although use of these agents could be considered in populations at high CVD risk along with close monitoring.

• #66 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #67 Diagnosis and management of non-alcoholic fatty liver disease (NAFLD) – American Gastroenterological AssociationAGA Logo_Horizontal

  https://gastro.org/clinical-guidance/diagnosis-and-management-of-non-alcoholic-fatty-liver-disease-nafld/

  21. Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. […] 23. Ursodeoxycholic acid (UDCA) is not recommended for the treatment of NAFLD or NASH. […] 24. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH but they may be considered as the first line agents to treat hypertriglyceridemia in patients with NAFLD. […] 43. Intensive lifestyle modification improves aminotransferases and liver histology in children with NAFLD and thus should be the first line of treatment. […] 44. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed. The effect of metformin administered at a higher dose is not known. […] 45. Vitamin E 800 IU/day (RRR α–tocopherol) offers histological benefits to children with biopsy-proven NASH or borderline NASH but confirmatory studies are needed before it’s use can be recommended in clinical practice.

• #68 Diagnosis and management of non-alcoholic fatty liver disease (NAFLD) – American Gastroenterological AssociationAGA Logo_Horizontal

  https://gastro.org/clinical-guidance/diagnosis-and-management-of-non-alcoholic-fatty-liver-disease-nafld/

  21. Vitamin E (α-tocopherol) administered at daily dose of 800 IU/day improves liver histology in non-diabetic adults with biopsy-proven NASH and therefore it should be considered as a first-line pharmacotherapy for this patient population. […] 23. Ursodeoxycholic acid (UDCA) is not recommended for the treatment of NAFLD or NASH. […] 24. It is premature to recommend omega-3 fatty acids for the specific treatment of NAFLD or NASH but they may be considered as the first line agents to treat hypertriglyceridemia in patients with NAFLD. […] 43. Intensive lifestyle modification improves aminotransferases and liver histology in children with NAFLD and thus should be the first line of treatment. […] 44. Metformin at 500 mg twice daily offers no benefit to children with NAFLD and thus should not be prescribed. The effect of metformin administered at a higher dose is not known. […] 45. Vitamin E 800 IU/day (RRR α–tocopherol) offers histological benefits to children with biopsy-proven NASH or borderline NASH but confirmatory studies are needed before it’s use can be recommended in clinical practice.

• #69 Fatty Liver: Overview, Etiology, Epidemiology

  https://emedicine.medscape.com/article/175472-overview

  Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are not recommended to treat NASH or NAFLD. […] Statins can be used to treat dyslipidemia in patients with NAFLD and NASH, but they should not be used specifically to treat NASH, pending evidence from randomized controlled trials. Statins should be avoided in patients with decompensated cirrhosis.

• #70 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  https://my.clevelandclinic.org/health/diseases/22437-non-alcoholic-fatty-liver-disease

  Your provider may discuss bariatric surgery with you. Bariatric surgery to support weight loss may reverse MASLD that’s diagnosed before you develop cirrhosis. […] Yes, but that depends on your situation. In general, treatment can reverse MASLD unless you have MASH-related cirrhosis. […] Taking steps, like losing weight, may reverse the impact MASLD has on your liver.

• #71 Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments – Thanapirom – Hepatobiliary Surgery and Nutrition

  https://hbsn.amegroups.org/article/view/22509/html

  The review did not comment on the current mainstay strategy for NASH treatment, which is weight reduction through lifestyle interventions. These include a combination of increase in exercise/physical activity and caloric restriction and should be individually tailored. Weight loss of 7% of total body weight is associated with improvement in histologic features of NASH, while a weight loss of 10% is associated with fibrosis regression regardless of the method used. […] Bariatric surgery is a promising option for reducing weight and metabolic complications. Although it is not yet an established therapy for NASH and more data are required to support its use for the liver disease component, some experts suggest considering bariatric surgery in morbidly obese non-cirrhotic patients who failed lifestyle modifications. […] Therefore, continuous research is required in order to better understand its pathogenesis, develop of non-invasive markers of severity and identify new therapeutic targets.

• #72 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Exercise notably decreases steatosis and the risk of NAFLD developing into NASH. […] Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are the most common means of bariatric surgery that aim to shrink the stomach. The mechanisms by which they attenuate NAFLD appear to be reduction of oxidative stress and inflammation. […] Biologically active substances, which are cheaper and have fewer side effects, are attractive treatment methods for NAFLD. […] Statins are mainly used to prevent cardiovascular disease and decrease LDL-cholesterol levels. An increasing number of studies suggested that statins were useful to reduce the risk of NAFLD. […] PPAR agonists are traditionally used for treating MetS by lowering TG and glucose levels. […] Cenicriviroc is an oral and dual antagonist of CCR2 and CCR5. It exerted anti-inflammatory and antifibrotic effects in a diet-induced NAFLD mouse model and weakened NAFLD.

• #73 Clinical Care Guidelines & Guidances in NAFLD/NASH – Global Liver Institute

  https://globalliver.org/clinical-care-guidelines-and-guidances-in-nafld-nash/

  Management of NAFLD or NASH should be done with multidisciplinary healthcare teams that include a primary care physician, hepatologist, gastroenterologist, and endocrinologist, as needed. […] Lifestyle modification is the preferred way to manage NAFLD/NASH long-term. […] In individuals with both NASH and type 2 diabetes, pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1 RA’s) should be considered. […] Weight management medications (semaglutide or liraglutide) are recommended when someone has NAFLD or NASH and a BMI of >27 kg/m2. […] For those who meet criteria for metabolic weight loss surgery, bariatric surgery can effectively resolve NAFLD or NASH in most patients who have not yet developed cirrhosis. […] People with NAFLD should be recommended a diet that leads to a calorie deficit, limiting carbohydrates and saturated fats and encouraging high fiber and unsaturated fats. […] Lifestyle modifications are necessary. A combination of proper nutrition and increased physical activity are shown to have positive results on NAFLD/NASH regression.

• #74 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  Exercise notably decreases steatosis and the risk of NAFLD developing into NASH. […] Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are the most common means of bariatric surgery that aim to shrink the stomach. The mechanisms by which they attenuate NAFLD appear to be reduction of oxidative stress and inflammation. […] Biologically active substances, which are cheaper and have fewer side effects, are attractive treatment methods for NAFLD. […] Statins are mainly used to prevent cardiovascular disease and decrease LDL-cholesterol levels. An increasing number of studies suggested that statins were useful to reduce the risk of NAFLD. […] PPAR agonists are traditionally used for treating MetS by lowering TG and glucose levels. […] Cenicriviroc is an oral and dual antagonist of CCR2 and CCR5. It exerted anti-inflammatory and antifibrotic effects in a diet-induced NAFLD mouse model and weakened NAFLD.

• #75 Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss | BMC Endocrine Disorders | Full Text

  https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-00980-1

  Weight loss is the primary therapy for most patients with NAFLD. Weight loss can improve liver biochemical tests, liver histology, serum insulin levels, and quality of life in patients with NAFLD. […] A significant body of literature has shown that weight loss induces a clinical improvement in patients with NAFLD or NASH. […] In the last few years there have been promising outcomes using pioglitazone (and related medication), but also the use of Glucagon-like peptide-1 (GLP-1) receptor agonists has shown significant improvement in hepatic outcomes in patients with NAFLD. […] Specifically looking at NAFLD related outcomes, bariatric and metabolic surgery has not been taken into account as treatment option in many meta-analyses to date, despite the increasing body of evidence and properly designed studies on this subject. […] A meta-analysis on 48 studies showed that the combination of pioglitazone and Roux-en Y Gastric Bypass surgery had the best effects on the NAFLD Activity Score.

• #76 Nonalcoholic Fatty Liver Disease: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2013/0701/p35.html

  Nonalcoholic fatty liver disease is characterized by excessive fat accumulation in the liver (hepatic steatosis). […] A healthy diet, weight loss, and exercise are first-line therapeutic measures to reduce insulin resistance. […] There is insufficient evidence to support bariatric surgery, metformin, thiazolidinediones, bile acids, or antioxidant supplements for the treatment of nonalcoholic fatty liver disease. […] The goals of therapy include the prevention or reversal of hepatic injury and fibrosis. […] Comorbid conditions, such as diabetes, hyperlipidemia, hypertension, or sleep apnea, should be addressed and treated appropriately. […] Statins are not contraindicated in patients with nonalcoholic fatty liver disease, and the risk of hepatotoxicity in these patients is not increased compared with the general population.

• #77 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  https://my.clevelandclinic.org/health/diseases/22437-non-alcoholic-fatty-liver-disease

  Metabolic dysfunction-associated steatotic liver disease (MASLD) is when fat builds up in your liver. It once was called nonalcoholic fatty liver disease (NAFLD). […] Losing weight and becoming more active may slow down or reverse liver damage from MASLD. […] Early diagnosis and treatment can keep MASLD from getting worse. […] Treatment for MASLD usually starts with weight loss. Your healthcare provider will also treat conditions like diabetes, high cholesterol and high blood pressure, which cause MASLD. […] Losing weight makes a difference in your liver health. Reducing excess fat in your liver helps with inflammation that leads to cirrhosis. […] Your provider may recommend meal plans like the Mediterranean diet or the DASH diet. […] Your healthcare provider may recommend weight loss medications like GLP-1 agonists if you have diabetes and/or obesity.

• #78 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Treatments for nonalcoholic fatty liver disease include weight loss, exercise, improved diabetes control and the use of cholesterol-lowering medications. […] The best treatment for you depends on the underlying cause of your nonalcoholic fatty liver disease. Preferred treatments include: […] Weight loss and exercise. If your body mass index is above 25, a diet and exercise program may reduce the amount of accumulated fat in your liver. […] Diabetes control – Strict management of diabetes with diet, medications or insulin lowers blood sugar, which may prevent further liver damage. […] Cholesterol control – Controlling elevated levels of cholesterol and triglycerides with diet, exercise and cholesterol-lowering medications may help stabilize or reverse nonalcoholic fatty liver disease.

• #79 Non-alcoholic fatty liver disease (NAFLD)

  https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/

  If detected and managed at an early stage, it’s possible to stop NAFLD getting worse and reduce the amount of fat in your liver. […] Most people with NAFLD will not develop any serious problems, but if you’re diagnosed with the condition it’s a good idea to take steps to stop it getting any worse. […] There’s currently no specific medication for NAFLD, but making healthy lifestyle choices can help. […] Treatment also may be recommended for associated conditions (high blood pressure, diabetes and cholesterol) or complications. […] There’s not currently any medicine that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] For example, your doctor may recommend medicine to treat high blood pressure, treat high cholesterol, treat type 2 diabetes and treat obesity.

• #80 Non-Alcoholic Fatty Liver Disease – NAFLD / NASH | Bucks County Gastroenterology Associates | Yardley | Newtown | Langhorne Pennsylvania

  https://www.buckscountygi.com/treatments-non-alcoholic-fatty-liver-disease.html

  Treatments for nonalcoholic fatty liver disease include weight loss, exercise, improved diabetes control and the use of cholesterol-lowering medications. […] The best treatment for you depends on the underlying cause of your nonalcoholic fatty liver disease. Preferred treatments include: […] Weight loss and exercise. If your body mass index is above 25, a diet and exercise program may reduce the amount of accumulated fat in your liver. […] Diabetes control – Strict management of diabetes with diet, medications or insulin lowers blood sugar, which may prevent further liver damage. […] Cholesterol control – Controlling elevated levels of cholesterol and triglycerides with diet, exercise and cholesterol-lowering medications may help stabilize or reverse nonalcoholic fatty liver disease.

• #81 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  We reviewed treatments whose mechanisms of action would respond to the pathophysiology of NAFLD, but at present have not been shown to be efficacious. […] Emerging treatments are not indicated for NASH but could be beneficial for that pathology based on preliminary studies, albeit evidence is still insufficient. […] Current pharmacologic treatments are limited, and they are only recommended in patients with NASH. […] It is important to always keep in mind that the main cause of mortality in those patients is cardiovascular, and so management must be integrated, treating each of the components of metabolic syndrome.

• #82 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  A multidisciplinary approach to treatment that involves nutritionists, endocrinologists, cardiologists, and other specialists as needed in addition to your hepatologist is essential to successfully manage the underlying metabolic conditions associated with fatty liver disease. […] In March 2024, the US Food and Drug Administration approved the use of resmetirom (Rezdiffra) for people with NASH and stage 2 or 3 fibrosis (but not cirrhosis) along with eating a healthy diet and participating in regular exercise. This is the first drug approved for NASH in the United States and the approval was based on resolution of NASH and improvement in fibrosis in about a quarter of the patients treated in a large international trial (MAESTRO NASH, NCT03900429). […] Some evidence suggests vitamin E supplements may be helpful for people with liver damage due to NAFLD and NASH. Researchers in one study found that a daily dose of the natural form of vitamin E the kind that comes from food sources and isnt made in a laboratory improved NASH in study participants overall by reducing fat and inflammation although not scarring.

• #83 Clinical Care Guidelines & Guidances in NAFLD/NASH – Global Liver Institute

  https://globalliver.org/clinical-care-guidelines-and-guidances-in-nafld-nash/

  Management of NAFLD or NASH should be done with multidisciplinary healthcare teams that include a primary care physician, hepatologist, gastroenterologist, and endocrinologist, as needed. […] Lifestyle modification is the preferred way to manage NAFLD/NASH long-term. […] In individuals with both NASH and type 2 diabetes, pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1 RA’s) should be considered. […] Weight management medications (semaglutide or liraglutide) are recommended when someone has NAFLD or NASH and a BMI of >27 kg/m2. […] For those who meet criteria for metabolic weight loss surgery, bariatric surgery can effectively resolve NAFLD or NASH in most patients who have not yet developed cirrhosis. […] People with NAFLD should be recommended a diet that leads to a calorie deficit, limiting carbohydrates and saturated fats and encouraging high fiber and unsaturated fats. […] Lifestyle modifications are necessary. A combination of proper nutrition and increased physical activity are shown to have positive results on NAFLD/NASH regression.

• #84 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  Nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD), is the buildup of extra fat in liver cells that is not caused by alcohol. […] We encourage adults living with MASH/NASH to visit our MASH Featured Clinical Trial page to learn more about potential opportunities in their area. […] There are no medications approved yet for nonalcoholic fatty liver disease (now called MASLD). Eating a healthy diet and adding physical movement to your day may help prevent liver damage from starting or reverse it in the initial stages. Here are suggestions for people who have NAFLD: See a liver specialist (gastroenterologist or hepatologist) to monitor and advise you about your liver health. […] There are things people can do to lower their chances of developing NAFLD (now called MASLD). They include: Maintain a healthy weight.

• #85 Comprehensive Nonalcoholic Fatty Liver Disease Program | Columbia Surgery

  https://columbiasurgery.org/liver/comprehensive-nonalcoholic-fatty-liver-disease-program

  Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Without treatment, it can cause significant liver damage. […] Our program provides long-term care for all aspects of NAFLD and NASH, utilizing a variety of tools: genetic testing, imaging, experimental therapeutics in clinical trials, and behavior modification. […] Our program develops new techniques to guide important lifestyle changes. […] We believe in mitigating the use of biopsies when possible and use noninvasive tests (NITs) to help evaluate risk and course of treatment for patients with NAFLD and NASH. […] Strong emphasis on translational research leading to better treatment and cures.

• #86 Clinical Care Guidelines & Guidances in NAFLD/NASH – Global Liver Institute

  https://globalliver.org/clinical-care-guidelines-and-guidances-in-nafld-nash/

  Management of NAFLD or NASH should be done with multidisciplinary healthcare teams that include a primary care physician, hepatologist, gastroenterologist, and endocrinologist, as needed. […] Lifestyle modification is the preferred way to manage NAFLD/NASH long-term. […] In individuals with both NASH and type 2 diabetes, pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1 RA’s) should be considered. […] Weight management medications (semaglutide or liraglutide) are recommended when someone has NAFLD or NASH and a BMI of >27 kg/m2. […] For those who meet criteria for metabolic weight loss surgery, bariatric surgery can effectively resolve NAFLD or NASH in most patients who have not yet developed cirrhosis. […] People with NAFLD should be recommended a diet that leads to a calorie deficit, limiting carbohydrates and saturated fats and encouraging high fiber and unsaturated fats. […] Lifestyle modifications are necessary. A combination of proper nutrition and increased physical activity are shown to have positive results on NAFLD/NASH regression.

• #87 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  A multidisciplinary approach to treatment that involves nutritionists, endocrinologists, cardiologists, and other specialists as needed in addition to your hepatologist is essential to successfully manage the underlying metabolic conditions associated with fatty liver disease. […] In March 2024, the US Food and Drug Administration approved the use of resmetirom (Rezdiffra) for people with NASH and stage 2 or 3 fibrosis (but not cirrhosis) along with eating a healthy diet and participating in regular exercise. This is the first drug approved for NASH in the United States and the approval was based on resolution of NASH and improvement in fibrosis in about a quarter of the patients treated in a large international trial (MAESTRO NASH, NCT03900429). […] Some evidence suggests vitamin E supplements may be helpful for people with liver damage due to NAFLD and NASH. Researchers in one study found that a daily dose of the natural form of vitamin E the kind that comes from food sources and isnt made in a laboratory improved NASH in study participants overall by reducing fat and inflammation although not scarring.

• #88 Comprehensive Nonalcoholic Fatty Liver Disease Program | Columbia Surgery

  https://columbiasurgery.org/liver/comprehensive-nonalcoholic-fatty-liver-disease-program

  Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Without treatment, it can cause significant liver damage. […] Our program provides long-term care for all aspects of NAFLD and NASH, utilizing a variety of tools: genetic testing, imaging, experimental therapeutics in clinical trials, and behavior modification. […] Our program develops new techniques to guide important lifestyle changes. […] We believe in mitigating the use of biopsies when possible and use noninvasive tests (NITs) to help evaluate risk and course of treatment for patients with NAFLD and NASH. […] Strong emphasis on translational research leading to better treatment and cures.

• #89 Fatty Liver Disease | MedlinePlus

  https://medlineplus.gov/fattyliverdisease.html

  Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. […] There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. […] The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. […] Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. […] If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains. Get regular exercise, which can help you lose weight and reduce fat in the liver.

• #90 Non-alcoholic fatty liver disease (NAFLD) | NHS inform

  https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/non-alcoholic-fatty-liver-disease-nafld/

  If detected and managed at an early stage, its possible to stop NAFLD getting worse and reduce the amount of fat in your liver. […] Most people with NAFLD wont develop any serious problems, but if youre diagnosed with the condition its a good idea to take steps to stop it getting any worse. […] Theres currently no specific medication for NAFLD, but making healthy lifestyle choices can help and treatment may be recommended for associated conditions (high blood pressure, diabetes and cholesterol) or complications. […] Adopting a healthy lifestyle is the main way of managing NAFLD. The following can all help. […] There isnt currently any medication that can treat NAFLD, but various medicines can be useful in managing the problems associated with the condition. […] If you develop severe cirrhosis and your liver stops working properly, you may need to be put on the waiting list for a liver transplant.

• #91 Nonalcoholic fatty liver disease – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/diagnosis-treatment/drc-20354573

  Treatment for NAFLD usually starts with weight loss. This can be done by eating a healthy diet, limiting portion sizes and exercise. Losing weight may improve other health problems that lead to NAFLD. Typically, losing 10% of your body weight or more is recommended. But losing even 3% to 5% of your starting weight can have benefits. Weight-loss surgery or medicines also may be helpful for certain people. […] A new medicine is available to treat people who have NASH with moderate to severe liver scarring. Resmetirom (Rezdiffra) can help reduce the amount of fat that collects in the liver. This medicine is not recommended for people with cirrhosis. For those who have cirrhosis due to NASH, a liver transplant may be needed.

• #92 Fatty Liver Disease: Nonalcoholic and Alcoholic Steatohepatitis (NAFLD/AFLD)

  https://www.webmd.com/fatty-liver-disease/fatty-liver-disease

  If you have complications due to either type of FLD, such as cirrhosis or liver failure, you may need to have a liver transplant. In general, people with MASH who get a liver transplant do very well. […] FLD can be reversed if you avoid alcohol and take steps to get to a healthy weight. The liver is one of the few organs in your body that can replace damaged tissue with new cells rather than with scar tissue. But that reversal only works if you don’t drink alcohol and follow a healthy lifestyle.

• #93 Non-Alcoholic Fatty Liver Disease (NAFLD): Diagnosis & Treatment | NewYork-Presbyterian

  https://www.nyp.org/digestive/liver-diseases/fatty-liver-disease-non-alcoholic/treatment

  How is NAFLD Treated? […] Improving liver health is the first approach to reversing NAFLD. Lifestyle changes, including regular physical activity, dietary changes, and maintaining a healthy body weight, are vital in supporting a healthy liver. Weight loss of 7% can improve liver fat and inflammation, and 10% weight loss can reverse liver fibrosis. […] There are no FDA-approved medications to treat fatty liver disease. Your doctor may advise you to take vitamin E or pioglitazone (a diabetes medication) to try to reduce the fat and inflammation in the liver. Many medications are currently being studied in clinical trials to determine if they effectively reduce fat, inflammation, and fibrosis in the liver. […] Severe liver cirrhosis can be life-threatening, which may increase the need for a liver transplant.

• #94

  https://link.springer.com/article/10.1007/s12325-019-00898-6

  Several drugs that are not specifically licensed for the treatment of NASH but with a potential benefit based on their mode of action have been tested. […] There is hence currently no pharmacological treatment that has NASH on its label. […] Meanwhile, patients with significant disease eligible for pharmacological treatment as defined above can be offered treatment in the context of a clinical trial. […] Numerous drugs are currently being tested for the treatment of NASH. […] As these phase 34 trials will take a long time, drugs can be granted conditional approval based on histological benefit, which is considered a reasonably likely surrogate for later clinical outcomes. […] As outlined before, progressive fibrosis is mainly responsible for the liver-related consequences of the disease in terms of cirrhosis and its complications.

• #95 Nonalcoholic Fatty Liver Disease (NAFLD)

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/

  Once NAFLD is determined, management of the condition focuses on lifestyle interventions (health dietary modifications and appropriate physical activities permitted during pregnancy) as there are no approved medications for NAFLD in pregnancy. […] We encourage adults living with NAFLD to visit our Clinical Trials page to learn more about opportunities in their area.

• #96 Treating inflammation to combat non-alcoholic fatty liver disease in: Journal of Endocrinology Volume 256 Issue 1 (2023)

  https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0194.xml

  Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic steatohepatitis (NASH) has become the most common chronic liver disease, thereby representing a great burden for patients and healthcare systems. Specific pharmacological therapies for NAFLD are still missing. […] Inflammation is an important driver in the pathogenesis of NASH, and the mechanisms underlying inflammation in NAFLD represent possible therapeutic targets. […] These approaches to target inflammation in NASH include inhibition of immune cell recruitment via chemokine receptors (e.g. cenicriviroc), neutralization of CD44 or galectin-3 as well as agonism to nuclear factors like peroxisome proliferator-activated receptors and farnesoid X receptor that interfere with the activation of immune cells.

• #97 Treating inflammation to combat non-alcoholic fatty liver disease in: Journal of Endocrinology Volume 256 Issue 1 (2023)

  https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0194.xml

  Thus, although cenicriviroc as a monotherapy missed to achieve significant improvement in fibrosis, a combination with a second therapeutic approach focused more on inhibiting metabolic injury represents a promising concept and is currently being investigated, for example, in combination with the FXR agonist tropifexor.

• #98 Current strategies for nonalcoholic fatty liver disease treatment (Review)

  https://www.spandidos-publications.com/10.3892/ijmm.2024.5412

  FXR regulated transcription in hepatocytes and maintained BA homeostasis. Abenavoli et al summarized that the mechanisms of obeticholic acid (OCA, an FXR agonist) to improve NAFLD in a pre-clinical setting included increasing insulin sensitivity, reducing lipid synthesis and hepatic fat accumulation, and ameliorating lipotoxicity, inflammation, oxidative stress and hepatic fibrosis.

• #99 Treating inflammation to combat non-alcoholic fatty liver disease in: Journal of Endocrinology Volume 256 Issue 1 (2023)

  https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0194.xml

  This includes compounds from the PPAR agonist group, elafibrinor […] and seladelpar […] The PPAR/ agonist elafibrinor failed to achieve significant resolution of NASH at 72 weeks in patients with NASH fibrosis F13 […] The apoptosis inhibitors selonsertib (ASK-1 inhibitor) and emricasan (caspase inhibitor) did not achieve higher rates of improvement in fibrosis compared with placebo control at 48 and 72 weeks, respectively. […] Currently, a wide variety of substances continue to be investigated in advanced clinical trials […] In addition, there are two adaptive IIb/III studies, one for cotadutide, a dual GLP-1 and glucagon agonist, and belapectin, a galectin 3 inhibitor. […] Other therapeutic approaches that target particularly inflammation are currently less advanced but represent a very important field of research in light of the failed therapeutic approaches with a primary focus on metabolic injury.

• #100 Treating inflammation to combat non-alcoholic fatty liver disease in: Journal of Endocrinology Volume 256 Issue 1 (2023)

  https://joe.bioscientifica.com/view/journals/joe/256/1/JOE-22-0194.xml

  Thus, although cenicriviroc as a monotherapy missed to achieve significant improvement in fibrosis, a combination with a second therapeutic approach focused more on inhibiting metabolic injury represents a promising concept and is currently being investigated, for example, in combination with the FXR agonist tropifexor.

• #101 The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease

  https://www.mdpi.com/1422-0067/22/24/13219

  Meta-analysis involving 782 patients with NAFLD showed evidence for the benefit of probiotics and synbiotics supplementation for liver steatosis, liver enzymes, lipid profiles, and liver stiffness. […] Cholesterol and triglyceride are the key toxic lipid mediators of liver injury. […] TRβ agonists stimulate fatty acid β-oxidation and oxidative phosphorylation in the liver. […] CCR2 plays a role in the infiltration of proinflammatory mediators at the site of liver injury, and CCR5 in the proliferation of collagen-producing cells. […] FGF19 plays a central role in regulating bile acids, carbohydrates, and energy metabolism. […] Since NASH is a multifactorial disease involving different contributing mechanisms, combination therapy is likely to show additional benefits when compared with monotherapy.

• #102 New approach in the treatment of non-alcoholic fatty liver disease (NAFLD)

  https://www.uni-jena.de/en/203940/new-approach-in-the-treatment-of-non-alcoholic-fatty-liver-disease-nafld

  The prebiotic resistant starch could play an important role in the treatment of non-alcoholic fatty liver disease (NAFLD) in the future. […] Initial indications suggest that a specially adapted diet with resistant starch not only positively influences the intestinal microbiome but also leads to an alleviation of the disease. […] The results have now been published in the current issue of the research journal Cell Metabolism. […] We found out that the participants in the study benefited from a resistant starch diet, as the accumulation of fat in the diseased liver was reduced. […] Furthermore, we observed an increase in certain types of bacteria in the gut of the participants; these bacteria positively influenced fat reduction and transport in the liver. […] In addition, reduced NAFLD and inflammation biomarkers indicate an alleviation of liver damage.

• #103 Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3378283/

  Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. […] Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. […] The current status of NAFLD therapy and an approach to its management is reviewed. […] The primary objective of any NAFLD therapy is improvement in steatohepatitis and fibrosis, with the ultimate goal of preventing CVD- and liver-related death. […] Nonpharmacological measures are aimed at reducing caloric intake and increasing physical activity levels. Weight loss and increased physical activity are effective in NAFLD treatment, and their role in CVD risk reduction is well established. […] Modest weight loss (7% to 10%) and exercise improve liver histology, insulin resistance (IR) and quality of life, and should form the backbone of any treatment strategy.

• #104 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. […] Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis. […] All patients with NAFLD require advice about lifestyle modification aimed at weight loss and increased physical activity, as well as treatment of any associated metabolic risk factors (diabetes, hypertension and dyslipidaemia). […] For patients with steatohepatitis and fibrosis who are at highest risk of developing progressive liver disease, more aggressive lifestyle modification is required and if this fails can be considered for liver-directed pharmacotherapy with pioglitazone or vitamin E.

• #105 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  https://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-S2255534X18300628

  Treatment with GLP-1 agonists is approved for diabetes and obesity. […] We reviewed treatments whose mechanisms of action would respond to the pathophysiology of NAFLD, but at present have not been shown to be efficacious. […] Emerging treatments are not indicated for NASH but could be beneficial for that pathology based on preliminary studies, albeit evidence is still insufficient. […] Hygienic-dietary measures have been shown to be efficacious for treating NAFLD and should be at the core of any therapeutic strategy. Current pharmacologic treatments are limited, and they are only recommended in patients with NASH.

• #106 Non-alcoholic fatty liver disease: a practical approach to treatment | Frontline Gastroenterology

  https://fg.bmj.com/content/5/4/277

  For patients with biopsy-proven NASH, where lifestyle intervention has failed, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered. […] Pioglitazone appears to be an effective treatment for NASH, but there are also some concerns about its long-term safety. […] Vitamin E is an antioxidant that has recently been shown to have beneficial effects on histology in non-diabetic patients with NASH. […] Lifestyle interventions aimed at weight loss and increased activity are essential for all patients with NAFLD and if sustained are effective in the treatment of NAFLD. For patients who fail lifestyle intervention, liver-directed pharmacotherapy with pioglitazone or vitamin E can be considered for those with advanced, but pre-cirrhotic, NASH.

• #107 Current treatment for non-alcoholic fatty liver disease | Revista de Gastroenterología de México

  http://www.revistagastroenterologiamexico.org/en-current-treatment-for-non-alcoholic-fatty-articulo-resumen-S2255534X18300628

  We reviewed treatments whose mechanisms of action would respond to the pathophysiology of NAFLD, but at present have not been shown to be efficacious. […] Emerging treatments are not indicated for NASH but could be beneficial for that pathology based on preliminary studies, albeit evidence is still insufficient. […] Current pharmacologic treatments are limited, and they are only recommended in patients with NASH. […] It is important to always keep in mind that the main cause of mortality in those patients is cardiovascular, and so management must be integrated, treating each of the components of metabolic syndrome.

• #108 Clinical Care Guidelines & Guidances in NAFLD/NASH – Global Liver Institute

  https://globalliver.org/clinical-care-guidelines-and-guidances-in-nafld-nash/

  Management of NAFLD or NASH should be done with multidisciplinary healthcare teams that include a primary care physician, hepatologist, gastroenterologist, and endocrinologist, as needed. […] Lifestyle modification is the preferred way to manage NAFLD/NASH long-term. […] In individuals with both NASH and type 2 diabetes, pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1 RA’s) should be considered. […] Weight management medications (semaglutide or liraglutide) are recommended when someone has NAFLD or NASH and a BMI of >27 kg/m2. […] For those who meet criteria for metabolic weight loss surgery, bariatric surgery can effectively resolve NAFLD or NASH in most patients who have not yet developed cirrhosis. […] People with NAFLD should be recommended a diet that leads to a calorie deficit, limiting carbohydrates and saturated fats and encouraging high fiber and unsaturated fats. […] Lifestyle modifications are necessary. A combination of proper nutrition and increased physical activity are shown to have positive results on NAFLD/NASH regression.

• #109 Nonalcoholic Steatohepatitis Treatment

  https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/nash-treatment/

  A multidisciplinary approach to treatment that involves nutritionists, endocrinologists, cardiologists, and other specialists as needed in addition to your hepatologist is essential to successfully manage the underlying metabolic conditions associated with fatty liver disease. […] In March 2024, the US Food and Drug Administration approved the use of resmetirom (Rezdiffra) for people with NASH and stage 2 or 3 fibrosis (but not cirrhosis) along with eating a healthy diet and participating in regular exercise. This is the first drug approved for NASH in the United States and the approval was based on resolution of NASH and improvement in fibrosis in about a quarter of the patients treated in a large international trial (MAESTRO NASH, NCT03900429). […] Some evidence suggests vitamin E supplements may be helpful for people with liver damage due to NAFLD and NASH. Researchers in one study found that a daily dose of the natural form of vitamin E the kind that comes from food sources and isnt made in a laboratory improved NASH in study participants overall by reducing fat and inflammation although not scarring.

• #110 Comprehensive Nonalcoholic Fatty Liver Disease Program | Columbia Surgery

  https://columbiasurgery.org/liver/comprehensive-nonalcoholic-fatty-liver-disease-program

  Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Without treatment, it can cause significant liver damage. […] Our program provides long-term care for all aspects of NAFLD and NASH, utilizing a variety of tools: genetic testing, imaging, experimental therapeutics in clinical trials, and behavior modification. […] Our program develops new techniques to guide important lifestyle changes. […] We believe in mitigating the use of biopsies when possible and use noninvasive tests (NITs) to help evaluate risk and course of treatment for patients with NAFLD and NASH. […] Strong emphasis on translational research leading to better treatment and cures.

• #111 NAFLD & NASH – Symptoms, Causes, Differences & Treatment Options PACE Hospitals – Best Hospitals in Hitech City, Hyderabad, India | Near Madhapur, Kukatpally, KPHB, Kondapur, Gachibowli, Jubilee Hills, Banjara HillsPACE Hospitals Contact

  https://www.pacehospital.com/non-alcoholic-fatty-liver-disease-causes-symptoms-diagnosis-and-treatment

  Although research continues to find drugs that are suitable for widespread use in the management of NAFLD, many well-designed trials have shown that lifestyle changes (exercise and diet) that lead to weight loss are effective in the management of this disease. […] The future of non-alcoholic fatty liver disease (NAFLD) lies in raising awareness; it will allow hepatologist to determine which people have this condition in order to treat them. […] People with Nonalcoholic fatty liver disease (NAFLD) can these steps to control and reverse it that includes: Healthy diet – Follow a healthy diet consist of whole grains, fruits, and leafy vegetables, especially rich in vitamin E. […] NAFLD can be reduced by knowing the reason of NAFLD like diabetes, obesity, dislipidimia, thyroid dysfunction or patients with hepatitis c, any cause which is found out if treated the NAFLD can be reduced. […] Yes, NAFLD can be reversed. […] NAFLD is curable with proper evaluation and treatment in time. […] NAFLD is not fatal but if we don’t diagnose and treat in time can lead to NASH and ultimately Cirrhosis of the liver and complication of it can lead to liver cancer.

• #112 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  https://my.clevelandclinic.org/health/diseases/22437-non-alcoholic-fatty-liver-disease

  Your provider may discuss bariatric surgery with you. Bariatric surgery to support weight loss may reverse MASLD that’s diagnosed before you develop cirrhosis. […] Yes, but that depends on your situation. In general, treatment can reverse MASLD unless you have MASH-related cirrhosis. […] Taking steps, like losing weight, may reverse the impact MASLD has on your liver.

Zobacz więcej